BR112012011576A2 - dna de minicírculos superenrolados para aplicações de terapia genética - Google Patents

dna de minicírculos superenrolados para aplicações de terapia genética

Info

Publication number
BR112012011576A2
BR112012011576A2 BR112012011576A BR112012011576A BR112012011576A2 BR 112012011576 A2 BR112012011576 A2 BR 112012011576A2 BR 112012011576 A BR112012011576 A BR 112012011576A BR 112012011576 A BR112012011576 A BR 112012011576A BR 112012011576 A2 BR112012011576 A2 BR 112012011576A2
Authority
BR
Brazil
Prior art keywords
gene therapy
supercoiled
dna
therapy applications
mini
Prior art date
Application number
BR112012011576A
Other languages
English (en)
Inventor
Brian E Gilbert
Daniel James Catanese
E Lynn Zechiedrich
Erol Bakkalbasi
Jonathan Fogg
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of BR112012011576A2 publication Critical patent/BR112012011576A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Abstract

dna de minicírculos superenrolados para aplicações de terapia genética. a presente invenção refere-se a composições de ácido nucleico molécula compreendendo minivetores que codificam uma sequência de àcido nucleico e os métodos de terapia génica utilizando munivetores que codificam uma sequência de ácido nucleico.
BR112012011576A 2009-10-16 2010-10-15 dna de minicírculos superenrolados para aplicações de terapia genética BR112012011576A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25245509P 2009-10-16 2009-10-16
PCT/US2010/052920 WO2011047318A2 (en) 2009-10-16 2010-10-15 Supercoiled minicircle dna for gene therapy applications

Publications (1)

Publication Number Publication Date
BR112012011576A2 true BR112012011576A2 (pt) 2015-09-15

Family

ID=43876905

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011576A BR112012011576A2 (pt) 2009-10-16 2010-10-15 dna de minicírculos superenrolados para aplicações de terapia genética

Country Status (10)

Country Link
US (3) US8460924B2 (pt)
EP (1) EP2488641B1 (pt)
JP (2) JP2013507934A (pt)
KR (1) KR20120094166A (pt)
AU (1) AU2010306645B2 (pt)
BR (1) BR112012011576A2 (pt)
CA (1) CA2777835A1 (pt)
MX (1) MX2012004447A (pt)
NZ (1) NZ599998A (pt)
WO (1) WO2011047318A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101510830B1 (ko) 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법
US20140056868A1 (en) * 2012-05-30 2014-02-27 University of Washington Center for Commercialization Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
EP2735614A1 (en) * 2012-11-22 2014-05-28 Centre National De La Recherche Scientifique In vitro production of DNA minicircles comprising less than 250 base pairs
AU2014262867B2 (en) * 2013-05-10 2019-12-05 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
GB201702500D0 (en) * 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
US20180305701A1 (en) 2017-03-14 2018-10-25 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
US20200048716A1 (en) 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
GB2606844A (en) 2019-09-18 2022-11-23 Intergalactic Therapeutics Inc Synthetic DNA vectors and methods of use
US20240093226A1 (en) 2021-09-10 2024-03-21 Baylor College Of Medicine Ultrapure minivectors for gene therapy
US20240100189A1 (en) 2021-09-10 2024-03-28 Twister Biotech, Inc Using minivectors to treat idiopathic pulmonary fibrosis
US20230190955A1 (en) 2021-10-21 2023-06-22 Baylor College Of Medicine Treatment of liver cancer or liver fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2626584B1 (fr) * 1988-01-28 1990-07-13 Agronomique Inst Nat Rech Sequence ars efficace chez yarrowia lipolytica et procede pour sa preparation
WO1994009127A2 (en) 1992-10-16 1994-04-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Supercoiled minicircle dna as as a unitary promoter vector
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
DE60141533D1 (de) 2000-12-08 2010-04-22 Life Technologies Corp Ukleinsäuremolekülen unter verwendung multipler erkennungsstellen
GB0108968D0 (en) 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
AU2002247848A1 (en) 2001-04-10 2002-10-28 Imperial College Innovations Limited Methods for the production of minicircles
WO2003064623A2 (en) 2002-01-31 2003-08-07 Washington State University Research Foundation Methods and vectors for facilitating site-specific recombination
AU2003273995A1 (en) 2002-06-05 2003-12-22 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
IL166612A0 (en) * 2002-08-29 2006-01-15 Univ Leland Stanford Junior Circular nucleic acid vectors and methods for making and using the same
US7288529B2 (en) 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same
DE50305146D1 (de) * 2003-06-10 2006-11-02 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
WO2006074166A2 (en) * 2005-01-06 2006-07-13 Benitec, Inc. Rnai agents for maintenance of stem cells
US7622252B2 (en) 2005-06-10 2009-11-24 Baylor College Of Medicine Generation of minicircle DNA with physiological supercoiling
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
CA2695385A1 (en) * 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders

Also Published As

Publication number Publication date
US8729044B2 (en) 2014-05-20
EP2488641A2 (en) 2012-08-22
CA2777835A1 (en) 2011-04-21
EP2488641B1 (en) 2019-01-23
US20110160284A1 (en) 2011-06-30
AU2010306645B2 (en) 2017-03-23
MX2012004447A (es) 2012-10-15
US9267150B2 (en) 2016-02-23
WO2011047318A8 (en) 2011-06-09
WO2011047318A3 (en) 2011-09-09
US20130316449A1 (en) 2013-11-28
US8460924B2 (en) 2013-06-11
JP2017046710A (ja) 2017-03-09
NZ599998A (en) 2014-11-28
US20120302625A1 (en) 2012-11-29
WO2011047318A2 (en) 2011-04-21
EP2488641A4 (en) 2013-11-13
KR20120094166A (ko) 2012-08-23
AU2010306645A1 (en) 2012-06-07
JP2013507934A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
BR112012011576A2 (pt) dna de minicírculos superenrolados para aplicações de terapia genética
CY1122167T1 (el) Αντινοηματικα νουκλεϊνικα οξεα
AR121761A2 (es) Polipéptidos que presentan actividad de fosfolipasa y polinucleótidos que codifican los mismos
AR113177A2 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican
CY1119491T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
AU2011356210A8 (en) Novel fucosyltransferases and their applications
IN2014CN00650A (pt)
IN2014CN00597A (pt)
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
CL2013001831A1 (es) Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2015000665A1 (es) Compuesto análogo de glucagón útil para prevenir ganancia de peso o promover pérdida de peso; ácido nucleico que lo codifica; vector; célula huésped; kit; y procedimiento de producción.
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
BR112014030007A2 (pt) minivetores superenrolados como uma ferramenta para reparação, alteração e substituição de dna
EA201270019A1 (ru) Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
ATE502122T1 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
EA201500659A1 (ru) Ацетилтрансферазы и их применение для получения каротиноидов
BR112015014987A2 (pt) Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
BRPI0819526B8 (pt) Sequência de ácido nucleico de precursor de mirna artificial, construção recombinante e método para reduzir a expressão de uma sequência alvo
BR112015023473A2 (pt) mutações acetil-coa carboxilase
NZ740630A (en) Polymethine compounds and their use as fluorescent labels
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.